Fempatch and Japan coma scale abnormal - a phase IV clinical study of FDA data
Summary:
We study 36 people who take Fempatch (estradiol) or have Japan coma scale abnormal. No report of Japan coma scale abnormal is found in people who take Fempatch.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Fempatch?
Fempatch has active ingredients of estradiol. eHealthMe is studying from 17 Fempatch users. Check the latest studies of Fempatch.
What is Japan Coma Scale Abnormal?
Japan coma scale abnormal is found to be associated with 1 drug and 38 conditions by eHealthMe. Check the latest studies of Japan coma scale abnormal.
No report is found.
Do you take Fempatch and have Japan coma scale abnormal?
- Check whether Japan coma scale abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Fempatch:
- Fempatch (17 reports)
Japan coma scale abnormal treatments and more:
- Japan coma scale abnormal (19 reports)
How severe was Japan coma scale abnormal and when was it recovered:
Expand to all the drugs that have ingredients of estradiol:
Browse all side effects of Fempatch:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Japan coma scale abnormal:
Browse all the conditions that are associated with Japan coma scale abnormal:
How the study uses the data?
The study uses data from the FDA. It is based on estradiol (the active ingredients of Fempatch) and Fempatch (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Hydrocortisone Butyrate and Trazodone Hydrochloride - 5 seconds ago
- Could Mannose cause Insomnia? - 7 seconds ago
- Could Dapsone cause Fluid Overload? - 7 seconds ago
- Could Opdivo cause Flatulence? - 18 seconds ago
- Could Plavix cause General Symptom? - 20 seconds ago
- Could Rinvoq cause Rashes? - 23 seconds ago
- Could Opsumit cause Enterocolitis? - 28 seconds ago
- Could Ibuprofen cause Borderline Personality Disorder? - 28 seconds ago
- Could Buspirone Hcl cause Gastric Ulcer? - 32 seconds ago
- Toradol vs. Lovenox, side effect and effectiveness comparison - 38 seconds ago